WO1999026927A3 - Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central - Google Patents

Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central Download PDF

Info

Publication number
WO1999026927A3
WO1999026927A3 PCT/US1998/024833 US9824833W WO9926927A3 WO 1999026927 A3 WO1999026927 A3 WO 1999026927A3 US 9824833 W US9824833 W US 9824833W WO 9926927 A3 WO9926927 A3 WO 9926927A3
Authority
WO
WIPO (PCT)
Prior art keywords
metabotropic glutamate
nervous system
central nervous
receptor antagonists
glutamate receptor
Prior art date
Application number
PCT/US1998/024833
Other languages
English (en)
Other versions
WO1999026927A2 (fr
Inventor
Wagenen Bradford C Van
Scott T Moe
Daryl L Smith
Susan M Sheehan
Irina Shcherbakova
Richard Travato
Ruth Walton
Robert Barmore
Eric G Delmar
Thomas M Stormann
Original Assignee
Nps Pharma Inc
Wagenen Bradford C Van
Scott T Moe
Daryl L Smith
Susan M Sheehan
Irina Shcherbakova
Richard Travato
Ruth Walton
Robert Barmore
Eric G Delmar
Thomas M Stormann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2000522085A priority Critical patent/JP2001524468A/ja
Application filed by Nps Pharma Inc, Wagenen Bradford C Van, Scott T Moe, Daryl L Smith, Susan M Sheehan, Irina Shcherbakova, Richard Travato, Ruth Walton, Robert Barmore, Eric G Delmar, Thomas M Stormann filed Critical Nps Pharma Inc
Priority to IL13625098A priority patent/IL136250A0/xx
Priority to AU15317/99A priority patent/AU771358B2/en
Priority to NZ505207A priority patent/NZ505207A/en
Priority to MXPA00004940A priority patent/MXPA00004940A/es
Priority to EP98959535A priority patent/EP1037878A2/fr
Priority to CA002311131A priority patent/CA2311131A1/fr
Publication of WO1999026927A2 publication Critical patent/WO1999026927A2/fr
Publication of WO1999026927A3 publication Critical patent/WO1999026927A3/fr
Priority to US09/573,347 priority patent/US6429207B1/en
Priority to IL136250A priority patent/IL136250A/en
Priority to US10/211,523 priority patent/US7053104B2/en
Priority to AU2004202776A priority patent/AU2004202776B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés et des compositions pharmaceutiques contenant lesdits composés, qui agissent comme antagonistes au niveau des récepteurs du glutamate métabotropes. Lesdits composés sont utiles pour le traitement de maladies et de troubles neurologiques. Des procédés de préparation desdits composés sont également décrits.
PCT/US1998/024833 1997-11-21 1998-11-20 Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central WO1999026927A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP98959535A EP1037878A2 (fr) 1997-11-21 1998-11-20 Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central
IL13625098A IL136250A0 (en) 1997-11-21 1998-11-20 Metabotropic glutamate receptor antagonist compounds
AU15317/99A AU771358B2 (en) 1997-11-21 1998-11-20 Metabotropic glutamate receptor antagonists for treating central nervous system diseases
NZ505207A NZ505207A (en) 1997-11-21 1998-11-20 Metabotropic glutamate receptor antagonists for treating central nervous system diseases
MXPA00004940A MXPA00004940A (es) 1997-11-21 1998-11-20 Antagonistas de receptor de glutamato metabotropico para tratar enfermedades del sistema nervioso central.
JP2000522085A JP2001524468A (ja) 1997-11-21 1998-11-20 中枢神経系疾患を治療するための代謝調節型グルタミン酸受容体アンタゴニスト
CA002311131A CA2311131A1 (fr) 1997-11-21 1998-11-20 Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central
US09/573,347 US6429207B1 (en) 1997-11-21 2000-05-19 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
IL136250A IL136250A (en) 1997-11-21 2000-05-21 Metabotropic glutamate receptor antagonist compounds
US10/211,523 US7053104B2 (en) 1997-11-21 2002-08-05 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
AU2004202776A AU2004202776B2 (en) 1997-11-21 2004-06-17 Metabotropic glutamate receptor antagonists for treating central nervous system diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6675897P 1997-11-21 1997-11-21
US60/066,758 1997-11-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/573,347 Continuation-In-Part US6429207B1 (en) 1997-11-21 2000-05-19 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases

Publications (2)

Publication Number Publication Date
WO1999026927A2 WO1999026927A2 (fr) 1999-06-03
WO1999026927A3 true WO1999026927A3 (fr) 1999-10-21

Family

ID=22071510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/024833 WO1999026927A2 (fr) 1997-11-21 1998-11-20 Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central

Country Status (9)

Country Link
EP (1) EP1037878A2 (fr)
JP (1) JP2001524468A (fr)
CN (2) CN1554649A (fr)
AU (2) AU771358B2 (fr)
CA (1) CA2311131A1 (fr)
IL (2) IL136250A0 (fr)
MX (1) MXPA00004940A (fr)
NZ (1) NZ505207A (fr)
WO (1) WO1999026927A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895050B2 (en) 2003-08-06 2014-11-25 Senomyx, Inc. Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1059090A4 (fr) * 1998-03-03 2002-02-27 Yamanouchi Pharma Co Ltd Medicaments contre l'infarcissement du cerveau
GB9823845D0 (en) * 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
GB9823847D0 (en) * 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
CN1361768A (zh) * 1999-06-02 2002-07-31 Nps药物有限公司 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途
EP1210338A2 (fr) * 1999-08-05 2002-06-05 IGT Pharma Inc. Derives de 1,4 benzodiazepine utiles dans le traitement de maladies liees au systeme nerveux central
EP1582519A3 (fr) * 1999-08-19 2005-12-21 Nps Pharmaceuticals, Inc. Composes heteropolycycliques et leur utilisation comme antagonistes des recepteurs glutamiques metabotropes
NZ517221A (en) * 1999-08-19 2004-01-30 Nps Pharma Inc Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
RU2259360C2 (ru) * 1999-10-15 2005-08-27 Ф.Хоффманн-Ля Рош Аг Производные бензодиазепина и лекарственное средство, их содержащее
DK1224175T3 (da) 1999-10-15 2004-07-12 Hoffmann La Roche Benzodiazepinderivater som metabotropiske glutamatreceptorantagonister
GB0007193D0 (en) * 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
BR0114253A (pt) 2000-10-02 2003-07-01 Janssen Pharmaceutica Nv Antagonistas de receptor de glutamato metabotrópico
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
BR0212787A (pt) * 2001-09-24 2005-01-25 Elan Pharm Inc Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
EA009334B1 (ru) * 2002-03-29 2007-12-28 Янссен Фармацевтика Н.В. Меченные радиоактивными изотопами производные хинолина и их применение в качестве лигандов метаботропного глутаматного рецептора
CN100357283C (zh) * 2002-04-02 2007-12-26 中国科学院上海药物研究所 一类甲硫氨酰氨肽酶抑制剂
WO2004014881A2 (fr) * 2002-08-09 2004-02-19 Astra Zeneca Ab Nouveaux composes
WO2004056744A1 (fr) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides utilises comme inhibiteurs de la hydroxysteroide deshydrogenase
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
EP1587796A1 (fr) * 2003-01-31 2005-10-26 AstraZeneca AB Derives de quinoxaline satures et leur utilisation en tant que ligands du recepteur du glutamate metabotropique
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
US7501416B2 (en) 2004-02-06 2009-03-10 Bristol-Myers Squibb Company Quinoxaline compounds and methods of using them
US9012494B2 (en) 2004-05-07 2015-04-21 Janssen Pharmaceutica N.V. Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
MY141198A (en) 2004-08-30 2010-03-31 Janssen Pharmaceutica Nv Tricyclic adamantylamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
KR101197674B1 (ko) 2004-08-30 2012-11-07 얀센 파마슈티카 엔.브이. １１-베타 하이드록시스테로이드 탈수소효소 저해제로서의 ｎ-2 아다만타닐-２-페녹시-아세트아미드 유도체
ZA200707482B (en) 2005-02-04 2008-12-31 Senomyx Inc Compounds comprising linked heteroaryl moieties and their use as novel umami flavour modifiers, tastants and taste enhancers for comestible compositions
CN101160285A (zh) 2005-03-17 2008-04-09 辉瑞大药厂 适用于治疗疼痛的n-(n-磺酰氨基甲基)环丙烷甲酰胺衍生物
GB0506133D0 (en) * 2005-03-24 2005-05-04 Sterix Ltd Compound
AR055329A1 (es) 2005-06-15 2007-08-15 Senomyx Inc Amidas bis-aromaticas y sus usos como modificadores de sabor dulce, saborizantes, y realzadores de sabor
US7338961B2 (en) * 2005-06-17 2008-03-04 Apogee Biotechnology Corporation Sphingosine kinase inhibitors
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
US7868008B2 (en) 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
JP5031745B2 (ja) * 2005-08-12 2012-09-26 アストラゼネカ アクチボラグ 代謝型グルタミン酸受容体増強性イソインドロン
WO2007037543A1 (fr) * 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. Dérivé de biarylamide
EP1957475A1 (fr) * 2005-10-21 2008-08-20 Merz Pharma GmbH & Co.KGaA Chromenones et leur utilisation en tant que modulateurs des recepteurs metabotropes au glutamate
RU2008129622A (ru) * 2005-12-20 2010-01-27 Новартис АГ (CH) Производные никотиновой кислоты в качестве модуляторов метаботропных глутаматных рецепторов
TW200804281A (en) 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
WO2007124152A2 (fr) 2006-04-21 2007-11-01 Senomyx, Inc. Compositions comestibles comprenant des composes aromatisants a gout sale a potentiel eleve et leurs procedes de production
TW200817385A (en) * 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
ATE488520T1 (de) 2006-08-04 2010-12-15 Merz Pharma Gmbh & Co Kgaa Pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin
US7964732B2 (en) 2006-11-17 2011-06-21 Pfizer Inc. Substituted bicyclocarboxyamide compounds
PT2083811T (pt) 2006-11-22 2017-01-23 Clinical Res Ass Llc Métodos de tratamento da síndrome de down, síndrome do x frágil e autismo
ES2388454T3 (es) 2007-03-22 2012-10-15 Astrazeneca Ab Derivados de quinolina para el tratamiento de enfermedades inflamatorias
CA2684760A1 (fr) 2007-04-19 2008-10-30 F. Hoffmann-La Roche Ag Derives du dihydro-benzo[b][1,4]diazepine-2-one sulfamide
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
CN101348461B (zh) * 2007-07-17 2011-10-05 西安利君制药有限责任公司 用于老年痴呆症治疗的n-(3-吡啶甲酰氧基)-3,5-二甲基-1-金刚烷胺或其可药用盐
EP2064959B1 (fr) 2007-10-31 2012-07-25 Symrise AG Néomenthylamides aromatiques en tant qu'agents aromatisants
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
US8211882B2 (en) * 2008-03-08 2012-07-03 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
US7790760B2 (en) 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
US8415333B2 (en) 2009-02-24 2013-04-09 Respiratorious Ab Bronchodilating diazaheteroaryls
WO2011109398A2 (fr) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Procédés et compositions pour le traitement du syndrome d'angelman et des troubles du spectre autistique
WO2011150380A1 (fr) 2010-05-28 2011-12-01 Xenoport, Inc. Méthodes de traitement du syndrome de l'x fragile, du syndrome de down, de l'autisme et des troubles associés
WO2012006760A1 (fr) * 2010-07-14 2012-01-19 Merck Sharp & Dohme Corp. Composés tricycliques comme modulateurs allostériques des récepteurs métabotropes au glutamate
WO2012009646A1 (fr) 2010-07-15 2012-01-19 Xenoport, Inc. Méthodes de traitement du syndrome de l'x fragile, du syndrome de down, de l'autisme et de troubles associés
WO2012072547A1 (fr) * 2010-11-30 2012-06-07 Bayer Cropscience Ag Dérivés pyrimidiques et leur utilisation comme agents de lutte antiparasitaire
KR102529578B1 (ko) * 2014-08-29 2023-05-09 (주)아모레퍼시픽 신규 아다만탄 유도체 화합물
CN114539170B (zh) * 2021-12-31 2023-05-16 华南农业大学 一种用于同时检测金刚烷胺、喹乙醇、氯霉素的半抗原、人工抗原及其制备方法和应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2050074A1 (de) * 1969-10-27 1971-05-06 E R Squibb & Sons Ine , New York, NY (V St A.) 4 (Adamantylaminoalkylamino) chinoline, deren Salze und Derivate, sowie Verfahren zu ihrer Herstellung und ihre Verwendung
US3632581A (en) * 1968-10-08 1972-01-04 American Home Prod Schiff bases of quinoxaline-2-carboxal-dehydes and their reduction products
DE2728248A1 (de) * 1976-06-24 1978-01-05 Debat Lab Nitroxolinderivate
EP0002066A1 (fr) * 1977-11-22 1979-05-30 Teva Pharmaceutical Industries Limited Adamantyl-2 hydrazines et compositions pharmaceutiques les contenant
EP0407192A2 (fr) * 1989-07-07 1991-01-09 Meiji Seika Kabushiki Kaisha Dérivés acyloxy-4-quinoléine et compositions insecticides et acaricides les contenant
JPH07179371A (ja) * 1993-12-21 1995-07-18 Canon Inc 液晶性化合物、それを含む液晶組成物、それを用いた液晶素子、それらを用いた表示方法、及び表示装置
WO1996005818A1 (fr) * 1994-08-19 1996-02-29 Nps Pharmaceuticals, Inc. Procedes et composes actifs au niveau des recepteurs de glutamate metabotropiques, destines au traitement d'affections et de troubles neurologiques
WO1996040641A1 (fr) * 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. Derives de sulfonamides servant a moduler l'adherence cellulaire

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2509728A1 (fr) * 1981-07-17 1983-01-21 Roussel Uclaf Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
IE902295A1 (en) * 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
JPH04211661A (ja) * 1990-03-28 1992-08-03 Otsuka Pharmaceut Co Ltd キノリン誘導体及び該誘導体を含有する抗潰瘍剤
JPH0441425A (ja) * 1990-06-07 1992-02-12 Tanabe Seiyaku Co Ltd ５―リポキシゲナーゼ阻害剤
AU4567193A (en) * 1992-07-10 1994-01-31 Laboratoires Glaxo S.A. Anilide derivatives
US5716944A (en) * 1994-07-04 1998-02-10 Takeda Chemical Industries, Ltd. Phosphonic acid compounds, their production and use
PL336628A1 (en) * 1997-05-03 2000-07-03 Smithkline Beecham Plc Derivatives of tetrahydroisoquinoline as modulators of d3 dopamine receptors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632581A (en) * 1968-10-08 1972-01-04 American Home Prod Schiff bases of quinoxaline-2-carboxal-dehydes and their reduction products
DE2050074A1 (de) * 1969-10-27 1971-05-06 E R Squibb & Sons Ine , New York, NY (V St A.) 4 (Adamantylaminoalkylamino) chinoline, deren Salze und Derivate, sowie Verfahren zu ihrer Herstellung und ihre Verwendung
DE2728248A1 (de) * 1976-06-24 1978-01-05 Debat Lab Nitroxolinderivate
EP0002066A1 (fr) * 1977-11-22 1979-05-30 Teva Pharmaceutical Industries Limited Adamantyl-2 hydrazines et compositions pharmaceutiques les contenant
EP0407192A2 (fr) * 1989-07-07 1991-01-09 Meiji Seika Kabushiki Kaisha Dérivés acyloxy-4-quinoléine et compositions insecticides et acaricides les contenant
JPH07179371A (ja) * 1993-12-21 1995-07-18 Canon Inc 液晶性化合物、それを含む液晶組成物、それを用いた液晶素子、それらを用いた表示方法、及び表示装置
WO1996005818A1 (fr) * 1994-08-19 1996-02-29 Nps Pharmaceuticals, Inc. Procedes et composes actifs au niveau des recepteurs de glutamate metabotropiques, destines au traitement d'affections et de troubles neurologiques
WO1996040641A1 (fr) * 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. Derives de sulfonamides servant a moduler l'adherence cellulaire

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
B. PRAGER ET AL.: "Beilsteins Handbuch der Organischen Chemie, 12. Bd.", 1929, VERLAG VON JULIUS SPRINGER, BERLIN, XP002101991 *
B. PRAGER ET AL.: "Beilsteins Handbuch der Organischen Chemie, 9. Bd.", 1926, VERLAG VON JULIUS SPRINGER, BERLIN, XP002101990 *
CHEMICAL ABSTRACTS, vol. 115, no. 7, 19 August 1991, Columbus, Ohio, US; abstract no. 70978a, N. S. KOZLOV ET AL.: "Synthesis of adamantane-type beta-amino ketones" page 733; XP002101994 *
F. HONG ET AL.: "Design, synthesis and pharmacological test of a quinoline based, nonpeptidic analogue of neurotensin(8-13)", J. CHEM. SOC., PERKIN TRANS. 1, vol. 14, 1997, pages 2083 - 2088, XP002101983 *
F. SZTARICSKAI ET AL.: "Synthese und virushemmende in-vitro-Wirkung neuerer 1-substituierter Adamantanderivate", PHARMAZIE, vol. 30, no. 9, 1975, pages 571 - 581, XP002101986 *
G. FENECH ET AL.: "Derivati amidici dell'acido 1-adamantancarbossilico a potenziale attivita antivirale ed antitumorale", BOLL. CHIM. FARM., vol. 118, no. 2, 1979, pages 78 - 87, XP002101981 *
H. ZIMMER, H. D. BENSON: "Kondensierte Imidazole; Versuche zur Synthese des 13,16- und 14,16-Diazasterin-Gerüstes", CHIMIA, vol. 26, no. 3, 1972, pages 131 - 133, XP002101985 *
H.-G. BOIT: "Beilsteins Handbuch der Organischen Chemie", 1970, SPRINGER-VERLAG, BERLIN, XP002101992 *
K. H. KIM ET AL.: "Quantitative Structure-Activity Relationship in 1-Aryl-2-(alkylamino)ethanol Antimalarials", J. MED. CHEM., vol. 22, no. 4, 1979, pages 366 - 391, XP002101988 *
L. C. MARCH ET AL.: "Antimalarials. 2. Dihydro-1,3-oxazinoquinolines and Dihydro-1,3-pyridobenzoxazines", J. MED. CHEM., vol. 16, no. 4, 1973, pages 337 - 342, XP002101989 *
M. ZANISI ET AL.: "Excitatory amino acids as modulators of gonadotropin secretion", AMINO ACIDS, vol. 6, no. 1, 1994, pages 47 - 56, XP002101984 *
N. G. KOZLOV, G. P. KOROTISHOVA: "Synthesis of 1-(1-adamantyl)-2,3-dihydroxy-3-R-1-propanones", ZH. OBSHCH. KHIM., vol. 66, no. 12, 1996, pages 2039 - 2041, XP002101987 *
PATENT ABSTRACTS OF JAPAN vol. 095, no. 010 30 November 1995 (1995-11-30) *
R. LUCKENBACH: "Beilsteins Handbuch der Organischen Chemie, 3. u. 4. Eg., 22. Bd.", 1979, SPRINGER-VERLAG, BERLIN, XP002101993 *
S. S. SABRI ET AL.: "Syntheses and Antibacterial Activity of Some New N-(3-Methyl-2-quinoxalyl) Amino Alcohols and Amine 1,4-Dioxides", J. CHEM. ENG. DATA, vol. 29, no. 2, 1984, pages 229 - 231, XP002101982 *
VESTSI AKAD. NAVUK BSSR, SER. KHIM. NAVUK, no. 1, 1991, pages 60 - 65 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895050B2 (en) 2003-08-06 2014-11-25 Senomyx, Inc. Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof

Also Published As

Publication number Publication date
CA2311131A1 (fr) 1999-06-03
MXPA00004940A (es) 2002-10-17
CN1158264C (zh) 2004-07-21
IL136250A (en) 2006-12-10
AU771358B2 (en) 2004-03-18
EP1037878A2 (fr) 2000-09-27
AU2004202776A1 (en) 2004-07-22
IL136250A0 (en) 2001-05-20
CN1554649A (zh) 2004-12-15
AU2004202776B2 (en) 2008-06-19
CN1285820A (zh) 2001-02-28
JP2001524468A (ja) 2001-12-04
WO1999026927A2 (fr) 1999-06-03
NZ505207A (en) 2003-10-31
AU2004202776A2 (en) 2004-07-22
AU1531799A (en) 1999-06-15

Similar Documents

Publication Publication Date Title
WO1999026927A3 (fr) Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central
EP1595871A3 (fr) Antagonistes du recepteur metabotrope duglutamate et leur utilisation pour le traitement des maladies du systeme nerveux central.
EP1679313A3 (fr) Composés hétéropolycycliques et leur utilisation comme antagonistes du récepteur glutamate métabotropique
MY131442A (en) Excitatory amino acid receptor antagonists
IL127244A (en) Substituted amines, methods of their preparation and pharmaceutical compositions containing them
EP0686629A3 (fr) Antagonistes des récepteurs de tachycinine cyclohexyliques
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
EP1382597A3 (fr) Composés modulateurs des récepteurs des stéroides et procédés d'utilisations
BG106762A (en) Polycycloalkylpurines as adenosine receptor antagonists
WO2001010846A3 (fr) Nouveaux composes de 1,4-benzodiazepine et derives de ces derniers
FI20002725A (fi) 2,5-diokso-2,5-dihydro-1Hbents[b]atsepiinit NMDA-reseptorin antagonisteina
WO1999029308A3 (fr) Procede pour lutter contre l'obesite
HUP9900883A3 (en) Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists
WO2004048318A8 (fr) Procede ameliore pour la preparation d'indenes 1,3-substitutees
PL335501A1 (en) Quinoxalinodiones
CA2259031A1 (fr) Composes modulateurs de recepteurs d'androgenes, leurs procedes de fabrication et d'utilisation
SI0832074T1 (en) Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 136250

Country of ref document: IL

Ref document number: 98813148.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2311131

Country of ref document: CA

Ref document number: 2311131

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/004940

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref document number: 2000 522085

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15317/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 505207

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1998959535

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998959535

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 15317/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 178023

Country of ref document: IL